Abstract #2758
Application of a biodegradable, macrocyclic, polydisulfide-based contrast agent for monitoring tumor angiogenesis using dynamic contrast enhanced MRI
Anthony S. Malamas 1 , Erlei Jin 1 , John Haaga 2 , and Zheng-Rong Lu 1
1
Case Western Reserve University, Cleveland,
OH, United States,
2
University
Hospital Case Medical Center, Cleveland, OH, United
States
A novel biodegradable polydisulfide-based macrocyclic
contrast agent was developed for dynamic contrast
enhanced (DCE) MRI. The new macromolecular agent
selectively extravasates from leaky tumor vessels, while
minimizing potentially toxic side effects due to
cleavage of disulfide bonds incorporated into its
backbone. This agent was utilized to study anti-angiogenic
effects of Bumetanide, an inhibitor of NKCC
cotransporters that has recently exhibited anti-tumoral
capabilities, in colon cancer xenografts. DCE-MRI
revealed that the polydisulfide contrast agent is able
to detect significant reductions in the permeability and
plasma volume fraction parameters, which were then
verified by a decrease in CD31 expression upon IHC
analysis.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
